Spark Therapeutics and Pfizer announce publication in The New England Journal of Medicine of Interim Data from phase 1/2 clinical trial of investigational gene therapy for Hemophilia B (page 2)

Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B.

Spark Therapeutics and Pfizer announce publication in The New England Journal of Medicine of Interim Data from phase 1/2 clinical trial of investigational gene therapy for Hemophilia B

Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The ...

Thu 7 Dec 17 from Eurekalert

Groundbreaking Gene Therapy Drastically Reduces Bleeding Episodes In Hemophilia B Patients

A hemophilia expert called the results "striking" and just another example of a gene therapy renaissance that has brought patients with rare inherited diseases closer to potential cures. In ...

Thu 7 Dec 17 from Kaiser Health News

  • Pages: 1 2

Bookmark

Bookmark and Share